D-dimer Human ProcartaPlex™ Simplex Kit
Invitrogen™

D-dimer Human ProcartaPlex™ Simplex Kit

The Human D-dimer Simplex ProcartaPlex Kit measures D-dimer protein and is designed to be combinable with other Simplex kits so that you can create your own multiplex panel that utilizes Luminex xMAP technology for protein detection/quantitation.
Have Questions?
Número de catálogoCantidad
EPX01A-12149-90196 pruebas
Número de catálogo EPX01A-12149-901
Precio (EUR)
349,00
Each
Cantidad:
96 pruebas
Precio (EUR)
349,00
Each
El kit de dímero D humano Simplex ProcartaPlex mide la proteína dimero D y está diseñado para combinarse con otros kits Simplex para que pueda crear su propio panel multiplex que utilice tecnología Luminex xMAP para la detección o cuantificación de proteínas. Cuando se combinan varios kits Simplex (es decir, cuando no se utiliza un panel multiplex preconfigurado), solo se necesita un kit de tampón (se vende por separado) para cada placa de ensayo, independientemente del tamaño del complejo.

Acerca de los ensayos ProcartaPlex para la plataforma Luminex

Los inmunoensayos ProcartaPlex se basan en los principios de ELISA tipo sándwich y utilizan dos anticuerpos altamente específicos que se enlazan a diferentes epítopos de una proteína para cuantificar todos los objetivos de proteína simultáneamente utilizando un instrumento Luminex. Los ensayos multiplex ProcartaPlex requieren tan solo 25 µl de plasma o suero o 50 µl de sobrenadante de cultivo celular y solo cuatro horas para obtener los resultados analizados.

Más resultados por muestra: mida múltiples objetivos de proteínas simultáneamente en una única muestra de 25–50 µl

Tecnología Luminex consolidada: plataforma de multiplexing de referencia para detección y cuantificación de proteínas

Los ensayos ProcartaPlex utilizan tecnología Luminex Xmap (perfil multianalito) para la detección y cuantificación simultáneas de hasta 65 proteínas diana en una sola muestra de 25–50 µl de plasma, suero, sobrenadantes de cultivo celular y otros fluidos corporales.

Los gránulos Luminex del ensayo ProcartaPlex se tiñen internamente con proporciones precisas de fluoróforos rojos e infrarrojos para crear firmas específicas que pueden ser identificadas por los sistemas de detección Luminex Xmap (por ejemplo, Luminex 200, FLEXMAP 3D y MAGPIX). Similar a un ELISA tipo sándwich, el ensayo ProcartaPlex utiliza pares de anticuerpos emparejados para identificar la proteína de interés. En un ensayo multiplex, cada gránulo espectralmente único se etiqueta con anticuerpos específicos para una sola proteína diana, y las proteínas ligadas se identifican con anticuerpos biotinilados y estreptavidina-R-ficoeritrina (RPE). La conjugación de anticuerpos específicos de proteínas con un gránulo distinto permite el análisis de varios analitos en un solo pocillo.

La diferencia más significativa entre un ensayo ProcartaPlex y uno ELISA es que el anticuerpo de captura del ensayo ProcartaPlex se conjuga con un gránulo y no se absorbe en el pocillo de la microplaca, por lo que los reactivos del ensayo ProcartaPlex flotan en la solución. Para la detección, el instrumento Luminex 200, por ejemplo, contiene dos láseres, uno para distinguir la firma espectral de cada gránulo y el segundo para cuantificar la cantidad de fluorescencia RPE, que es proporcional a la cantidad de proteína presente en la muestra. Los ensayos multiplex ProcartaPlex pueden perfilar más proteínas diana utilizando mucha menos muestra en el mismo tiempo que se tarda en realizar un ELISA tipo sándwich tradicional.

Los paneles multiplex ProcartaPlex están disponibles en múltiples formatos en seis especies (humano, ratón, rata, primate no humano, porcino y canino). Visite thermofisher.com/procartaplex para obtener más información, incluida una lista completa de dianas proteicas individuales.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.

Especificaciones
Intervalo del ensayoSegún lo determinado para el lote 1: 317,99-1 302 500 pg/ml
Sensibilidad del ensayoSegún lo determinado para el lote 1: 132 pg/mL, Menos del 15 %
Tipo de esferaDímero D [44]
Para utilizar con (equipo)Instrumentos Luminex™, Instrumentos Luminex™
FormatoKit Simplex
génicacadena alfa del fibrinógeno
Alias de genFib2
ID de gen (Entrez)2243
Símbolo de genFGA
Línea de productosProcartaPlex, ProcartaPlex
ExpresiónCadena alfa del fibrinógeno
Tipo de muestraSobrenadantes de cultivo celular, suero y plasma, Plasma, Cell Culture Supernatants
Volumen de muestraSuero, plasma: 25 µl; CCS: 50 µl, Suero, plasma: 25 μl; CCS: 50 μl
Condiciones de envíoHielo húmedo
ID. de UniProtP02671
CombinabilityCombinable
Tipo de productoKit Simplex
Cantidad96 pruebas
Research AreaImmunology
EspecieHumano
Unit SizeEach
Contenido y almacenamiento
• 1 vial de gránulos de captura (50x)
• 1 vial de anticuerpo de detección biotinilado (50x)
• 2 viales de dímero D estándar humano (liofilizado)

Almacenar a 2–8 °C.

Preguntas frecuentes

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Citations & References (5)

Citations & References
Abstract
Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls.
Authors:van den Dries L, Claassen MAA, Groothuismink ZMA, van Gorp E, Boonstra A
Journal:Virology
PubMed ID:28644978
'Sustained immune activation during chronic HIV infection is considered to augment co-morbidity and mortality. Effective combination antiretroviral therapy (cART) has shown to dampen immune activation especially during the first year cART, but the effects of long-term cART in patients without major comorbidities remains under-investigated. We performed a comprehensive analysis including ... More
The host response in critically ill sepsis patients on statin therapy: a prospective observational study.
Authors:Wiewel MA, Scicluna BP, van Vught LA, Hoogendijk AJ, Zwinderman AH, Lutter R, Horn J, Cremer OL, Bonten MJ, Schultz MJ, van der Poll T
Journal:Ann Intensive Care
PubMed ID:29349709
'Statins can exert pleiotropic anti-inflammatory, vascular protective and anticoagulant effects, which in theory could improve the dysregulated host response during sepsis. We aimed to determine the association between prior statin use and host response characteristics in critically ill patients with sepsis.' ... More
Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis; a case control study.
Authors:Wiewel MA, Huson MA, van Vught LA, Hoogendijk AJ, Klein Klouwenberg PM, Horn J, Lutter R, Cremer OL, Schultz MJ, Bonten MJ, van der Poll T
Journal:Crit Care
PubMed ID:27719675
'Sepsis is a prominent reason for intensive care unit (ICU) admission in patients with HIV. We aimed to investigate the impact of HIV infection on presentation, outcome and host response in sepsis.' ... More
Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients.
Authors:Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, Ong DS, Cremer OL, Horn J, Franitza M, Toliat MR, Nürnberg P, Zwinderman AH, Bonten MJ, Schultz MJ, van der Poll T
Journal:Blood
PubMed ID:26956172
Preclinical studies have suggested that platelets influence the host response during sepsis. We sought to assess the association of admission thrombocytopenia with the presentation, outcome, and host response in patients with sepsis. Nine hundred thirty-one consecutive sepsis patients were stratified according to platelet counts (very low <50 × 10(9)/L, intermediate-low ... More
Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients.
Authors:van Vught LA, Scicluna BP, Hoogendijk AJ, Wiewel MA, Klein Klouwenberg PM, Cremer OL, Horn J, Nürnberg P, Bonten MM, Schultz MJ, van der Poll T
Journal:Crit Care
PubMed ID:27495247
Diabetes is associated with chronic inflammation and activation of the vascular endothelium and the coagulation system, which in a more acute manner are also observed in sepsis. Insulin and metformin exert immune modulatory effects. In this study, we aimed to determine the association of diabetes and preadmission insulin and metformin ... More